FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA?

Today's Daily Dose brings you news about Akero's near-term catalyst; FDA denying approval to Heron's HTX-011 for the management of postoperative pain and Intercept's OCA for treatment of NASH; Kiniksa's RHAPSODY trial results, PDS Biotechnology's KOL meeting and regulatory update on Verrica's VP-102.

from RTT - Top Story https://ift.tt/2BLPetP
via IFTTT